Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Giovanni Storto, Amalia De Renzo, Teresa Pellegrino, Fabiana Perna, Teresa De Falco, Paola Erra, Anna Nardelli, Antonio Speranza, Michele Klain, Bruno Rotoli, Leonardo Pace

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fluorine 18 (18F) fluorodeoxyglucose (FDG) combined positron emission tomographic-computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twenty-three consecutive patients (10 women, 13 men; mean age, 51.8 years ± 7.3 [standard deviation]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, 18F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete (n = 12) or partial (n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These findings were all confirmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% (P <.05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identification of patients needing additional therapeutic strategies.

Original languageEnglish
Pages (from-to)245-252
Number of pages8
JournalRadiology
Volume254
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Radioimmunotherapy
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Electrons
Fluorodeoxyglucose F18
Education
Follicular Lymphoma
ibritumomab tiuxetan
Kaplan-Meier Estimate
Informed Consent
Analysis of Variance
Therapeutics
Organizations
Survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. / Storto, Giovanni; De Renzo, Amalia; Pellegrino, Teresa; Perna, Fabiana; De Falco, Teresa; Erra, Paola; Nardelli, Anna; Speranza, Antonio; Klain, Michele; Rotoli, Bruno; Pace, Leonardo.

In: Radiology, Vol. 254, No. 1, 01.2010, p. 245-252.

Research output: Contribution to journalArticle

Storto, G, De Renzo, A, Pellegrino, T, Perna, F, De Falco, T, Erra, P, Nardelli, A, Speranza, A, Klain, M, Rotoli, B & Pace, L 2010, 'Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma', Radiology, vol. 254, no. 1, pp. 245-252. https://doi.org/10.1148/radiol.09090603
Storto, Giovanni ; De Renzo, Amalia ; Pellegrino, Teresa ; Perna, Fabiana ; De Falco, Teresa ; Erra, Paola ; Nardelli, Anna ; Speranza, Antonio ; Klain, Michele ; Rotoli, Bruno ; Pace, Leonardo. / Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. In: Radiology. 2010 ; Vol. 254, No. 1. pp. 245-252.
@article{d2fec26632f4424aa5788054d1ef4a10,
title = "Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma",
abstract = "Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fluorine 18 (18F) fluorodeoxyglucose (FDG) combined positron emission tomographic-computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twenty-three consecutive patients (10 women, 13 men; mean age, 51.8 years ± 7.3 [standard deviation]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, 18F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete (n = 12) or partial (n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These findings were all confirmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49{\%} or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49{\%} (P <.05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identification of patients needing additional therapeutic strategies.",
author = "Giovanni Storto and {De Renzo}, Amalia and Teresa Pellegrino and Fabiana Perna and {De Falco}, Teresa and Paola Erra and Anna Nardelli and Antonio Speranza and Michele Klain and Bruno Rotoli and Leonardo Pace",
year = "2010",
month = "1",
doi = "10.1148/radiol.09090603",
language = "English",
volume = "254",
pages = "245--252",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

AU - Storto, Giovanni

AU - De Renzo, Amalia

AU - Pellegrino, Teresa

AU - Perna, Fabiana

AU - De Falco, Teresa

AU - Erra, Paola

AU - Nardelli, Anna

AU - Speranza, Antonio

AU - Klain, Michele

AU - Rotoli, Bruno

AU - Pace, Leonardo

PY - 2010/1

Y1 - 2010/1

N2 - Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fluorine 18 (18F) fluorodeoxyglucose (FDG) combined positron emission tomographic-computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twenty-three consecutive patients (10 women, 13 men; mean age, 51.8 years ± 7.3 [standard deviation]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, 18F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete (n = 12) or partial (n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These findings were all confirmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% (P <.05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identification of patients needing additional therapeutic strategies.

AB - Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 (90Y)-ibritumomab tiuxetan radioimmunotherapy (RIT) by using fluorine 18 (18F) fluorodeoxyglucose (FDG) combined positron emission tomographic-computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non-Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twenty-three consecutive patients (10 women, 13 men; mean age, 51.8 years ± 7.3 [standard deviation]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, 18F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete (n = 12) or partial (n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These findings were all confirmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% (P <.05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identification of patients needing additional therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=75349106075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75349106075&partnerID=8YFLogxK

U2 - 10.1148/radiol.09090603

DO - 10.1148/radiol.09090603

M3 - Article

C2 - 20032155

AN - SCOPUS:75349106075

VL - 254

SP - 245

EP - 252

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -